Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 28;25(3):568.
doi: 10.3390/molecules25030568.

Approaches to PET Imaging of Glioblastoma

Lindsey R Drake  1   2 , Ansel T Hillmer  1   2   3   4 , Zhengxin Cai  1   2
Affiliations
Review

Approaches to PET Imaging of Glioblastoma

Lindsey R Drake et al. Molecules. .

Abstract

Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approximately three in 100,000 adults annually. Positron emission tomography (PET) imaging provides an important non-invasive method of measuring biochemically specific targets at GBM lesions. These powerful data can characterize tumors, predict treatment effectiveness, and monitor treatment. This review will discuss the PET imaging agents that have already been evaluated in GBM patients so far, and new imaging targets with promise for future use. Previously used PET imaging agents include the tracers for markers of proliferation ([11C]methionine; [18F]fluoro-ethyl-L-tyrosine, [18F]Fluorodopa,[18F]fluoro-thymidine, and [18F]clofarabine), hypoxia sensing ([18F]FMISO, [18F]FET-NIM, [18F]EF5, [18F]HX4, and [64Cu]ATSM), and ligands for inflammation. As cancer therapeutics evolve toward personalized medicine and therapies centered on tumor biomarkers, the development of complimentary selective PET agents can dramatically enhance these efforts. Newer biomarkers for GBM PET imaging are discussed, with some already in use for PET imaging other cancers and neurological disorders. These targets include Sigma 1, Sigma 2, programmed death ligand 1, poly-ADP-ribose polymerase, and isocitrate dehydrogenase. For GBM, these imaging agents come with additional considerations such as blood-brain barrier penetration, quantitative modeling approaches, and nonspecific binding.

Keywords: GBM; IDH; PARP; PD-L1; PET imaging; Sigma 1; Sigma 2; biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Radiotracers for markers of cellular proliferation.
Figure 2
Figure 2
Hypoxia-sensing tracers.
Figure 3
Figure 3
TSPO ligand.
Figure 4
Figure 4
Sigma 1 receptor radioligands.
Figure 5
Figure 5
Sigma 2 receptor radioligands.
Figure 6
Figure 6
Small molecule PD-L1 inhibitor.
Figure 7
Figure 7
PARP ligands.
Figure 8
Figure 8
Isocitrate dehydrogenase (IDH) radioligands.
See this image and copyright information in PMC

References

    1. Glioblastoma Multiforme. [(accessed on 15 November 2019)]; Available online: https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Gl....
    1. Louis D.N., Perry A., Reifenberger G., Von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1. - DOI - PubMed
    1. Amelot A., De Cremoux P., Quillien V., Polivka M., Adle-Biassette H., Lehmann-Che J., Francoise L., Carpentier A.F., George B., Mandonnet E., et al. IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS ONE. 2015;10:e0130596. doi: 10.1371/journal.pone.0130596. - DOI - PMC - PubMed
    1. Perrin S.L., Samuel M.S., Koszyca B., Brown M.P., Ebert L.M., Oksdath M., Gomez G.A. Glioblastoma heterogeneity and the tumour microenvironment: Implications for preclinical research and development of new treatments. Biochem. Soc. Trans. 2019;47:625–638. doi: 10.1042/BST20180444. - DOI - PubMed
    1. Ozdemir-Kaynak E., Qutub A.A., Yesil-Celiktas O. Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy. Front. Physiol. 2018;9 doi: 10.3389/fphys.2018.00170. - DOI - PMC - PubMed

MeSH terms